8Sztein MB, Serrate SA. Characterization of the immunoregulatary properties of thymosin α1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol, 1989, 11: 789.
9Zitvogel L, Taahara H, Cai Q, et al. Construction and chracterization of retroviral vectors expressing biologically active human interleukin-12.Hum Gen Ther, 1994,5: 1493.
10Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood, 1996,87: 3877.
3Bruce K, Rubin, Kater AP, et al. Thymosin 4 Seques- ters Actin in Cystic Fibrosis Sputum and Decreases Spu- tum Cohesivity in Vitro[J]. Chest, 2006, 130:1433 - 1440.
4Li YM, Chen H, Li X, et al. A New Immunomodu/atory Therapy for Severe Sepsis: Ulirmstatin Plus Thymosin l[J]. J Intensive Care Med, 2009,24:47-53.
5Ghany MG, Strader DB, Thomas DL, et al.Diagnosis, management, and treatment of hepatitis C : an update[J].Hepatology, 2009,49:1335.
6McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific As-so- ciation for the Study of the Liver consensus statements on the di-agno- sis management and treatment of hepatitis C virus infection[J]. JGastro- enterol Hepatol, 2007,22: 615.
8Beasley R. The Global Burden of Asthma Report, Global Initiative for Asthma ( GINA ) [ EB/OL ]. [ 2006 ]. ht- tp ://www. ginasthma, org.
9Shieh Y H, Huang H M, Wang C C, et al. Zerumboneenhances the Thl response and ameliorates ovalbumin-in- duced Th2 responses and airway inflammation in mice [ J ]. Int Immunopharmacol, 2015,24 ( 2 ) : 383 -391.
10Blumchen K, Kallinich T, Hamelmann E. Interleukin-5 : a novel target for asthma therapy[ J]. Exper Opin Biol T- her, 2001,1(3) :433-453.
